Swiss National Bank
SLNO

Swiss National Bank’s Soleno Therapeutics SLNO Stock Holding History

Swiss National Bank’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90,300
Closed -$3.02M – 2348
2026
Q1 		$3.02M Buy
90,300
+1,200
+1% +$47K ﹤0.01% 1635
2025
Q4 		$4.13M Buy
89,100
+12,400
+16% +$680K ﹤0.01% 1458
2025
Q3 		$5.18M Buy
76,700
+14,400
+23% +$1.07M ﹤0.01% 1311
2025
Q2 		$5.22M Buy
62,300
+12,200
+24% +$913K ﹤0.01% 1270
2025
Q1 		$3.58M Buy
50,100
+4,200
+9% +$205K ﹤0.01% 1441
2024
Q4 		$2.06M Buy
45,900
+9,900
+28% +$513K ﹤0.01% 1839
2024
Q3 		$1.82M Buy
36,000
+7,200
+25% +$345K ﹤0.01% 1920
2024
Q2 		$1.18M Sell
28,800
-1,300
-4% -$55.1K ﹤0.01% 2092
2024
Q1 		$1.29M Buy
30,100
+7,300
+32% +$330K ﹤0.01% 2092
2023
Q4 		$918K Buy
+22,800
New +$649K ﹤0.01% 2287

Swiss National Bank's SLNO Position: Q2 2026 in Review

Swiss National Bank sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 90,300 shares — an estimated $3.02M sold.

Swiss National Bank first reported a position in SLNO in Q4 2023 and held it in 10 quarters. The position peaked at $5.22M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Swiss National Bank reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Swiss National Bank sold 90,300 Soleno Therapeutics shares in Q2 2026, an estimated $3.02M.
  • Swiss National Bank first reported a position in Soleno Therapeutics in Q4 2023 and held it in 10 quarters.
  • Swiss National Bank's Soleno Therapeutics position peaked at $5.22M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.